Correction to “Real‐World Practitioner Perceptions of CARTITUDE‐4 Results for Patients With Previously Treated Multiple Myeloma”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMultiple Myeloma Research and Treatments
Balanean A, Baird S, Dulka B, Jennings‐Zhang L, Bone RN, Jeune‐Smith Y, et al. Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma. eJHaem. 2024;5:1154‐64. https://doi.org/10.1002/jha2.1047
In Figure 3 the “After” percentages for two response options were inadvertently transposed in the figure, creating an inconsistency with the description provided in the text.
Specifically:
The “After” result for the response option “I favor CAR T‐cell therapy in earlier lines (e.g., 2L or 3L settings)” should be 55% (not 31%).
The “After” result for the response option “I want real‐world and long‐term outcomes data on CAR T‐cell therapy in any line” should be 31% (not 55%).
We apologize for this error.